OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the ...

Contacts. OSE Immunotherapeutics Sylvie Détry [email protected] +33 153 198 757 Investor Relations Thomas Guillot [email protected] +33 607 380 431 Media U.S. Media: LifeSci ...

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant At the American Transplant Congress 2024 (June 1-5 ...

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market ...

OSE Immunotherapeutics has shared survival data behind a therapeutic vaccine’s phase 2 pancreatic cancer win as the French biotech continues to point to its “pipeline in a product” potential ...

Learn to use your lower body properly and generate more power in your golf swing with this top teacher's simple drill. The post Use this ‘chair drill’ to cure the early extension in your swing ...

The situation led OSE to consider the high, 850 mg dose cohort to be the primary analysis. In that group of 99 patients, OSE saw a 0.82 placebo-adjusted reduction in the average Mayo score ...

Finally the first release of Eudora OSE (Open Source Edition) For those who didn't know, Eudora was a rather popular commercial email client that was available up till a few years ago.

OSE Immunotherapeutics SA announced that the trial’s Independent Drug Safety Monitoring Board (DSMB) provided a positive recommendation on the continuation until its completion of the phase 2 clinical ...

OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the ...

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that the Japanese Patent Office has issued the notice of allowance for a new patent covering Tedopi®, a ...

This new collaboration between OSE Immunotherapeutics and MAbSilico aims to: Accelerate the development of OSE’s "Immunotherapy 2.0" drug candidates by using AI, including machine learning and ...